Pfizer
Transforming the Care of Animals for a Healthier World
Dr. James Messamore explains how a 100 fold reduction in reagent consumption and reduced hands-on and analysis time helps scientists at Pfizer Animal Health to faster go/no decision making and reduced cost.
Evaluation of Tau Phosphorylation using the Gyrolab Immunoassay Platform
With the help of data from biomarker assays aimed at quantifying the protein Tau, Dr Durham explains how fast assay development on Gyrolab workstation facilitates decision making and progress while querying kinase pathways on the phosphorylation of Tau. The speed with which data is generated is supporting researchers in their effort to understand the mechanisms behind Alzheimer’s disease.
From culture dish to patients: Translational biomarkers for Alzheimer's disease on a nano-scale
Dr Durham describes the processes involved in validating biomarkers for the monitoring of progression of Alzheimer’s disease and the effectiveness of new treatments using DELFIA and Gyros platforms. Twelve separate analytical methods were assessed and successfully validated and proved robust and reproducible for the analysis of biomarkers and plasma.
AstraZeneca
Development of assays for phosphorylated and total glycogen synthase as a translational peripheral biomarker for GSK3 activity using Gyrolab Workstation
MerckSerono
A complex protein in a complex matrix: how to meet the challenge with Gyrolab
Quotient Bioresearch
PK and PD analysis of proteins in different matrices using Gyrolab
Dr Roberts uses Cytokine IL-8 model analyte to compare various emerging analytical techniques and presents data comparisons for the different methods. He also presents data for four different analytes in serum using minimum required dilutions of between 1/2 and 1/20 in three different species.
ICON Development Solutions (formerly Veeda)
Use of Gyrolab in a Contract Research Environment.
Dr Chappell evaluates the relative performance of Gyrolab compared to other techniques with particular attention to data generated in development of Amyloid Beta and Cytokine assays. He also discusses Gyrolab’s ability to run robust multiplex assays.